ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (“Sciele”) (NASDAQ: SCRX), today announced that, pursuant to the terms of the indenture relating to its 2.625% Contingent Convertible Senior Notes Due 2027 (the “Notes”), it has designated October 8, 2008, as the “anticipated effective date” of the Make-Whole Fundamental Change that will occur as a result of the transaction (the “Transaction”) whereby Sciele will become an indirect wholly owned subsidiary of Shionogi & Co., Ltd. (the “Parent”) pursuant to the previously announced Agreement and Plan of Merger (the “Merger Agreement”) dated September 1, 2008, among Sciele, the Parent, and Tall Bridge, Inc., an indirect wholly owned subsidiary of the Parent (the “Merger Sub”). Holders of the outstanding Notes may exercise their conversion rights beginning on September 8, 2008, in accordance with, and subject to, the provisions of the Notes and the related indenture.
